Top

Cancer Causes & Control

Published in:

01-12-2008 | Original Paper

Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions

Authors: Nancy Krieger, Jarvis T. Chen, James H. Ware, Afamia Kaddour

Published in: Cancer Causes & Control | Issue 10/2008

Abstract

Objective

To test whether reported associations between race/ethnicity and breast cancer estrogen receptor (ER) status are inflated due to missing ER data, lack of socioeconomic data, and use of the odds ratio (OR) rather than the prevalence ratio (PR).

Methods

We geocoded and added census tract socioeconomic data to all cases of primary invasive breast cancer (n = 42,420) among women diagnosed between 1998 and 2002 in two California cancer registries (San Francisco Bay Area; Los Angeles County) and analyzed the data using log binomial regression.

Results

Adjusting for socioeconomic position and tumor characteristics, in models using the imputed data, reduced the PR for the black versus white excess risk of being ER− from 1.76 (95% CI: 1.66, 1.86; adjusted for age and catchment area) to 1.47 (95% CI: 1.38, 1.56). The latter parameter estimate was 16% greater (i.e., 1.56) in models excluding women with missing ER data, and was 43% greater when estimated using the OR (i.e., 1.82).

Conclusion(s)

Studies on race/ethnicity and ER status that fail to account for missing data and socioeconomic data and report the OR are likely to yield inflated estimates of racial/ethnic disparities in ER status.

Althuis MD, Fergenbaumm JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13:1558–1568PubMed

Ademuyiwa FO, Olopade OI (2003) Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev 22:47–53. doi:10.1023/A:1022259901319 PubMedCrossRef

Chlebowski RT, Chen Z, Anderson GL et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97:439–448PubMedCrossRef

Stanford JL, Szklo M, Brinton LA (1986) Estrogen receptors and breast cancer. Epidemiol Rev 8:42–59PubMed

Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients—a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results Database. Cancer 110:876–884. doi:10.1002/cncr.22836 PubMedCrossRef

Watlington AT, Byers T, Mouchawar J, Sauaia A, Ellis J (2007) Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer? Cancer 109:2093–2099. doi:10.1002/cncr.22640 PubMedCrossRef

Woods SE, Luking R, Atkins B, Engel A (2006) Association of race and breast cancer stage. J Natl Med Assoc 98:683–686PubMed

Cunningham JE, Butler WM (2004) Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis. Breast Cancer Res Treat 88:161–176. doi:10.1007/s10549-004-0592-9 PubMedCrossRef

Porter PL, Lund MJ, Lin MG et al (2004) Racial differences in the expression of cell cycle regulatory proteins in breast carcinoma - Study of young African American and white women in Atlanta, Georgia. Cancer 100:2533–2542. doi:10.1002/cncr.20279 PubMedCrossRef

10.

Gill KS, Yankaskas BC (2004) Screening mammography performance and cancer detection among black women and white women in community practice. Cancer 100:139–148. doi:10.1002/cncr.11878 PubMedCrossRef

11.

Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K (2004) Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarker Prev 13:2090–2095

12.

Althuis MD, Brogan DD, Coates RJ et al (2003) Breast cancers among very young premenopausal women (United States). Cancer Causes Control 14:151–160. doi:10.1023/A:1023006000760 PubMedCrossRef

13.

Li CI, Malone KE, Daling JR (2002) Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarker Prev 11:601–607

14.

Miller BA, Hankey BF, Thomas TL (2002) Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155:534–545. doi:10.1093/aje/155.6.534 PubMedCrossRef

15.

Furberg H, Millikan R, Dressler L, Newman B, Geradts J (2001) Tumor characteristics in African American and white women. Breast Cancer Res Treat 68:33–43. doi:10.1023/A:1017994726207 PubMedCrossRef

16.

Elledge RM, Clark GM, Chamness GC, Osborne CK (1994) Tumor biologic factors and breast-cancer prognosis among White, Hispanic, and Black women in the United-States. J Natl Cancer Inst 86:705–712. doi:10.1093/jnci/86.9.705 PubMedCrossRef

17.

Harlan LC, Coates RJ, Block G et al (1993) Estrogen receptor status and dietary intakes in breast cancer patients. Epidemiology 4:25–31. doi:10.1097/00001648-199301000-00006 PubMedCrossRef

18.

Stanford JL, Greenberg RS (1989) Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 79:71–73PubMed

19.

Stanford JL, Szklo M, Boring CC et al (1987) A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol 125:184–194PubMed

20.

Martinez ME, Nielson CM, Nagle R, Lopez AM, Kim C, Thompson P (2007) Breast cancer among Hispanic and non-Hispanic white women in Arizona. J Health Care Poor Underserved 18:130–145. doi:10.1353/hpu.2007.0112 PubMedCrossRef

21.

Menes TS, Ozao J, Kim U (2007) Breast cancer and ethnicity: strong association between reproductive risk factors and estrogen receptor status in Asian patients—a retrospective study. Breast J 13:352–358. doi:10.1111/j.1524-4741.2007.00442.x PubMedCrossRef

22.

Gordon N (2003) Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev 22:55–65. doi:10.1023/A:1022212018158 PubMedCrossRef

23.

Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509–2515. doi:10.1002/(SICI)1097-0142(19981215)83:12<2509::AID-CNCR15>3.0.CO;2-V

24.

Krieger N, van den Eeden SK, Zava D, Okamoto A (1997) Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco Bay Area. Ethn Dis 7:137–149PubMed

25.

Weiss SE, Tartter PI, Ahmed S et al (1995) Ethnic differences in risk and prognostic factors for breast cancer. Cancer 76:268–274. doi: 10.1002/1097-0142(19950715)76:2<268::AID-CNCR2820760217>3.0.CO;2-1

26.

Gordon NH (1995) Association of education and income with estrogen receptor status in primary breast cancer. Am J Epidemiol 142:796–803PubMed

27.

Chen VW, Correa P, Kurman RJ et al (1994) Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 3:127–135PubMed

28.

Ansell D, Whitman S, Lipton R, Cooper R (1993) Race, income, and survival from breast cancer at two public hospitals. Cancer 72:2974–2978. doi:10.1002/1097-0142(19931115)72:10<2974::AID-CNCR2820721019>3.0.CO;2-M

29.

Crowe JP Jr, Gordon NH, Hubay CA, Pearson OH, Marshall JS, McGuire WL (1986) The interaction of estrogen receptor status and race in predicting prognosis for stage I breast cancer patients. Surgery 100:599–605PubMed

30.

Schafer JL (1997) Analysis of incomplete multivariate data. Chapman and Hall, Boca Raton

31.

Greenland S, Finkle WD (1995) A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 142:1255–1264PubMed

32.

Rubin D (1976) Inference and missing data. Biometrika 63:581–592. doi:10.1093/biomet/63.3.581 CrossRef

33.

Haggstrom DA, Quale C, Smith-Bindman R (2005) Differences in the quality of breast cancer care among vulnerable populations. Cancer 104:2347–2358. doi:10.1002/cncr.21443 PubMedCrossRef

34.

Cross CK, Harris J, Recht A (2002) Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies. Cancer 95:1988–1999. doi:10.1002/cncr.10830 PubMedCrossRef

35.

Hwang ES, Chew T, Shiboski S, Farren G, Benz CC, Wrensch M (2005) Risk factors for estrogen receptor-positive breast cancer. Arch Surg 140:58–62. doi:10.1001/archsurg.140.1.58 PubMedCrossRef

36.

Thomson CS, Hole DJ, Twelves CJ, Brewster DH, Black RJ, Scottish Cancer Therapy Network (2001) Prognostic factors in women with breast cancer: distribution by socioeconomic status and effect on differences in survival. J Epidemiol Community Health 55:308–315. doi:10.1136/jech.55.5.308 PubMedCrossRef

37.

Krieger N (2008) Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 37:627–637. doi:10.1093/ije/dyn055 PubMedCrossRef

38.

Krieger N (2005) Stormy weather: “race”, gene expression, and the science of health disparities. Am J Public Health 95:2155–2160. doi:10.2105/AJPH.2005.067108 PubMedCrossRef

39.

Krieger N (2003) Does racism harm health? did child abuse exist before 1962?—on explicit questions, critical science, and current controversies: an ecosocial perspective. Am J Public Health 93:194–199PubMed

40.

Ernst W, Harris B (eds) (1999) Race, science, and medicine, 1700–1960. Routledge, London

41.

Krieger N (1994) Epidemiology and the web of causation: has anyone seen the spider? Soc Sci Med 39:887–903. doi:10.1016/0277-9536(94)90202-X PubMedCrossRef

42.

Krieger N (2004) Ecosocial theory. In: Anderson N (ed) Encyclopedia of health and behavior. Sage, Thousand Oaks, CA, pp 292–294

43.

Krieger N (2008) What’s level got to do with it?—proximal, distal, and the politics of causation. Am J Public Health 98:221–230. doi:10.2105/AJPH.2007.111278 PubMedCrossRef

44.

Davies HT, Crombie IK, Tavakoli M (1998) When can odds ratios mislead? BMJ 316:989–991PubMed

45.

Zocchetti C, Consonni D, Bertazzi PA (1997) Relationship between prevalence rate ratios and odds ratios in cross-sectional studies. Int J Epidemiol 26:220–223. doi:10.1093/ije/26.1.220 PubMedCrossRef

46.

Greenland S, Thomas DC, Morgenstern H (1986) The rare-disease assumption revisited: a critique of “estimators of relative risk for case-control studies”. Am J Epidemiol 124:869–883PubMed

47.

Northern California Cancer Center (2008) http://www.nccc.org/site/c.foJNIXOyEpH/b.2577075/k.BE87/Home.htm. Accessed 22 May 2008

48.

Los Angeles Cancer Surveillance Program (2008) http://www.usc.edu/schools/medicine/departments/preventive_medicine/divisions/epidemiology/research/csp/index.html. Accessed 22 May 2008

49.

Krieger N, Chen JT, Waterman PD, Rehkopf DH, Yin R, Coull BA (2006) Race/ethnicity and changing US socioeconomic gradients in breast cancer incidence: California and Massachusetts, 1978–2002. Cancer Causes Control 17:217–226. doi:10.1007/s10552-005-0408-1 PubMedCrossRef

50.

US Office of Management and Budget (2008) Revisions to the standards for the classification of federal data on race and ethnicity. Federal register notice, October 30, 1997. http://www.whitehouse.gov/omb/fedreg/1997standards.html. Accessed 22 May 2008

51.

Stewart SL, Swallen KC, Glaser SL, Horn-Ross PL, West DW (1998) Adjustment of cancer incidence rates for ethnic misclassification. Biometrics 54:774–781. doi:10.2307/3109783 PubMedCrossRef

52.

Gomez SL, Kelsey JL, Glaser SL, Lee MM, Sidney S (2005) Inconsistencies between self-reported ethnicity and ethnicity recorded in a health maintenance organization. Ann Epidemiol 15:71–79. doi:10.1016/j.annepidem.2004.03.002 PubMedCrossRef

53.

Stewart SL, Swallen KC, Glaser SL, Horn-Ross PL, West DW (1999) Comparison of methods for classifying Hispanic ethnicity in a population-based cancer registry. Am J Epidemiol 149:1063–1071PubMed

54.

Swallen KC, West DW, Stewart SL, Glaser SL, Horn Ross PL (1997) Predictors of misclassification of Hispanic ethnicity in a population-based cancer registry. Ann Epidemiol 7:200–206. doi:10.1016/S1047-2797(96)00154-8 PubMedCrossRef

55.

Clegg LX, Reichman ME, Hankey BF et al (2007) Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control 18:177–187PubMedCrossRef

56.

Krieger N, Waterman P, Lemieux K, Zierler S, Hogan JW (2001) On the wrong side of the tracts? Evaluating the accuracy of geocoding in public health research. Am J Public Health 91:1114–1116PubMed

57.

Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV (2005) Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health 95:312–323. doi:10.2105/AJPH.2003.032482 PubMedCrossRef

58.

Krieger N, Chen JT, Waterman PD, Rehkopf DH, Subramanian SV (2003) Race/ethnicity, gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic measures—The Public Health Disparities Geocoding Project. Am J Public Health 93:1655–1671PubMed

59.

Krieger N, Chen JT, Waterman PD, Soobader MJ, Subramanian SV, Carson R (2002) Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: The Public Health Disparities Geocoding Project. Am J Epidemiol 156:471–482. doi:10.1093/aje/kwf068 PubMedCrossRef

60.

US Bureau of the Census. Poverty areas (2008) http://www.census.gov/population/socdemo/statbriefs/povarea.html. Accessed 22 May 2008.61

61.

King G, Honaker J, Joseph A, Scheve K (2001) Analyzing incomplete political science data: an alternative algorithm for multiple imputation. Am Pol Sci Review 95: 49–69

62.

Spiegelman D, Hertzmark E (2005) Easy SAS calculations for risk or prevalence ratios or differences. Am J Epidemiol 162:199–200. doi:10.1093/aje/kwi188 PubMedCrossRef

63.

Greenland S (2004) Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 160:301–305. doi:10.1093/aje/kwh221 PubMedCrossRef

64.

McNutt LA, Wu C, Xue X, Hafner JP (2003) Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 157:940–943. doi:10.1093/aje/kwg074 PubMedCrossRef

65.

Skov T, Deddens J, Petersen MR, Endahl L (1998) Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol 27:91–95. doi:10.1093/ije/27.1.91 PubMedCrossRef

66.

SAS Institute (2001) SAS language reference, Version 8. SAS Institute, Cary, NC

67.

Krieger N, Williams D, Moss N (1997) Measuring social class in US public health research: concepts, methodologies and guidelines. Annu Rev Public Health 18:341–378. doi:10.1146/annurev.publhealth.18.1.341 PubMedCrossRef

68.

Davey Smith G (2000) Learning to live with complexity: ethnicity, socioeconomic position, and health in Britain and the United States. Am J Public Health 90:1694–1698

69.

Galobardes B, Lynch J, Davey Smith G (2007) Measuring socioeconomic position in health research. Br Med J 81–82:21–37

70.

Goodman AH (2000) Why genes don’t count (for racial differences in health). Am J Public Health 90:1699–1702PubMedCrossRef

71.

Parra EJ, Kittles RA, Shriver MD (2004) Implications of correlations between skin color and genetic ancestry for biomedical research. Nature Genetics 36(suppl):S54–S60. doi:10.1038/ng1440

72.

Feldman MW, Lewontin RC, King MC (2003) Race: a genetic melting-pot. Nature 424:374. doi:10.1038/424374a PubMedCrossRef

73.

Fowler AM, Alarid ET (2007) Amping up estrogens receptors in breast cancer. Breast Cancer Res 9:305 (doi:10.1186/box1748). doi:10.1186/bcr1748

74.

Zhu K, Bernard LJ, Levine RS, Williams SM (1997) Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease? Med Hypotheses 49:69–75. doi:10.1016/S0306-9877(97)90255-3 PubMedCrossRef

75.

Petitti D (2004) Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol 33:461–463. doi: 10.1093/ije/dyh192

76.

Lawlor DA, Davey Smith G, Ebrahim S (2004) Commentary: The hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol 33:464–467. doi:10.1093/ije/dyh124 PubMedCrossRef

77.

Krieger N (2007) Why epidemiologists cannot afford to ignore poverty. Epidemiology 18:658–663PubMed

78.

Prentice RL, Chlebowski RT, Stefanick ML, Mansons JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O’Sullivan MJ, Rossouw JE, Anderson GL (2008). Conjugated equine estrogens and breast cancer risk in the Women’s Health Initiative clinical trial and observational study. Am J Epidemiol 167:1407–1415. doi:10.1093/aje/kwn090 PubMedCrossRef

79.

Clarke CA, Glaser SL (2007) Declines in breast cancer after the WHI: apparent impact of hormone therapy. Cancer Causes Control 18:847–852. doi:10.1007/s10552-007-9029-1 PubMedCrossRef

80.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. New Engl J Med 356:1670–1674. doi:10.1056/NEJMsr070105 PubMedCrossRef

81.

Kim S, Egerter S, Cubbin C, Takahashi ER, Braveman P (2007) Potential implications of missing income data in population-based surveys: an example from a postpartum survey in California. Public Health Reports 122:753–764PubMed

82.

Chen JT, Kaddour A, Krieger N (2008) Re: Kim et al, “Potential Implications of missing income data in population-based surveys”. Public Health Reports 123:260PubMed

Title: Race/ethnicity and breast cancer estrogen receptor status: impact of class, missing data, and modeling assumptions
Authors: Nancy Krieger
Jarvis T. Chen
James H. Ware
Afamia Kaddour
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 10/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9202-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion(s)

Please log in to get access to this content

Other articles of this Issue 10/2008

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study

Trends in testicular germ cell cancer incidence in Australia

Coffee and caffeine intake and the risk of ovarian cancer: the Iowa Women’s Health Study

Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada

Cancer incidence among pesticide applicators exposed to captan in the Agricultural Health Study

Re: Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries

Keynote webinar | Spotlight on antibody–drug conjugates in cancer